Skip to main content
SpringerLink
Log in

Sexualhormone

  • Chapter
Arzneiverordnungs-Report 2015

  • 1941 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American College of Obstetricians and Gynecologists (2013): Committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thrombo- embolism. Obstet Gynecol 121: 887–890

    Article  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2003): Rote Hand Brief zur Hormontherapie im Klimakterium vom 09.12.2003. Im Internet: www.akdae.de/20/40/index. html.

  • Arzneimittelkommission der deutschen Ärzteschaft (2011): Risiko von venösen Thromboembolien bei Einnahme von Drospirenon-haltigen kombinierten oralen Kontrazeptiva (Yasmin /Yasminelle, Aida, Yaz, Petibelle ). Dtsch Ärztebl 108: A244–2

    Google Scholar 

  • Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBras- seur N, Fiore LD, Bhasin S (2010): Adverse events associated with testosterone administration. N Engl J Med 363: 109–122.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Biglia N, Carinelli S, Maiorana A, D'Alonzo M, Lo Monte G, Marci R (2014): Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther 8: 285–292

    PubMed Central  CAS  PubMed  Google Scholar 

  • Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group (2007): Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840–845

    Article  Google Scholar 

  • Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995): Estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9–16

    Article  CAS  PubMed  Google Scholar 

  • Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emer- gency contraception. Cochrane Database Syst Rev. 2004; (3): CD001324

    Google Scholar 

  • Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators (2010): Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684–1692

    Article  CAS  PubMed  Google Scholar 

  • Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contra- ceptives and menopausal treatment. Lancet Oncol 6: 552–553

    Google Scholar 

  • Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006): Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108: 1089–1097

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ford O, Lethaby A, Roberts H, Mol BW (2012): Progesterone for premenstrual syndrome.

    Google Scholar 

  • Cochrane Database Syst Rev. 2012 Mar 14;3:CD003415 Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933–1001

    Google Scholar 

  • Gronich N, Lavi I, Rennert G (2011): Higher risk of venous thrombosis associated with dros- pirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319–1325

    Article  Google Scholar 

  • Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators (2008): Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299: 1036–1045

    Article  CAS  PubMed  Google Scholar 

  • Hilbert-Walter A, Büttner R, Sieber C, Bollheimer C (2013): Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137: 2117–2122

    Google Scholar 

  • Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differ- ing progestagen components. Lancet 346: 1589–1593

    Article  CAS  PubMed  Google Scholar 

  • Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9

    Article  Google Scholar 

  • LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators (2011): Health outcomes after stopping conjugated equine estrogens among postmeno- pausal women with prior hysterectomy: a randomized controlled trial. JAMA 305: 1305131–4

    Article  Google Scholar 

  • Lidegaard 0, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E (2011): Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 25;343:d6423

    Google Scholar 

  • Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E (2013): Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344: e299–0

    Google Scholar 

  • Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM (2006): A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13: 737–743

    Article  PubMed  Google Scholar 

  • McFadyen IJ, Forrest APM, Raab GM, Macintyre CCA (1989): Progesterone cream for cyclic breast pain. Brit Med J 289: 93–1

    Google Scholar 

  • Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427

    Article  Google Scholar 

  • Million Women Study Collaborators (2005): Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551

    Article  Google Scholar 

  • Million Women Study Collaborators (2007): Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–1710

    Article  Google Scholar 

  • Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16–23

    Article  CAS  PubMed  Google Scholar 

  • NAMS Advisory Panel (2003): Amended report from the NAMS Advisory Panel on postmeno- pausal hormone therapy. Menopause 10: 6–12

    Article  Google Scholar 

  • Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620.

    Article  CAS  PubMed  Google Scholar 

  • Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182

    Article  CAS  PubMed  Google Scholar 

  • Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007): The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670–1674

    Article  CAS  PubMed  Google Scholar 

  • Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546

    Google Scholar 

  • Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434

    Article  CAS  PubMed  Google Scholar 

  • Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-con- trol study. Brit Med J 312: 83–88

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Van Grootheest K, Vrieling T (2003): Thromboembolism associated with the new contraceptive Yasmin. BMJ 326: 25–7

    Article  Google Scholar 

  • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588

    Article  Google Scholar 

  • Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 291: 1701–1712

    Article  Google Scholar 

  • Writing Group for the Women's Health Initiative Investigators (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333

    Article  Google Scholar 

  • Yang LP, Plosker GL (2012): Nomegestrol acetate/estradiol: in oral contraception. Drugs 72: 1917–1928

    Article  CAS  PubMed  Google Scholar 

  • Zbuk K, Anand SS (2013): Declining incidence of breast cancer after decreased use of hor- mone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66: 1–7

    Article  Google Scholar 

Download references

Authors
  1. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Schwabe, U. (2015). Sexualhormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_41

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_41

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation